Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Conclusions
The unique renal-specific mechanism of action and favorable efficacy and safety profile of SGLT2 inhibitors support consideration of these antidiabetes agents as a treatment option for patients with T2DM.
Source: The Diabetes Educator - Category: Endocrinology Authors: Vivian, E. Tags: Features Source Type: research
More News: Canagliflozin | Clinical Trials | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | Insulin | Invokana | Jardiance | SGLT2 Inhibitors | Urology & Nephrology